The diagnostic value of CYFRA 21-1 in oral squamous cell carcinoma: a meta-analysis.

IF 2.9 3区医学 Q2 ONCOLOGY

Expert Review of Anticancer Therapy Pub Date : 2024-11-01 Epub Date: 2024-09-23 DOI:10.1080/14737140.2024.2405225

Yuting Liang, Zhenke Yi, Jiajin Li, Jufeng Ye

{"title":"The diagnostic value of CYFRA 21-1 in oral squamous cell carcinoma: a meta-analysis.","authors":"Yuting Liang, Zhenke Yi, Jiajin Li, Jufeng Ye","doi":"10.1080/14737140.2024.2405225","DOIUrl":null,"url":null,"abstract":"Background: Previous studies have revealed the importance of CYFRA 21-1 in the diagnosis of oral squamous cell cancer (OSCC). However, the results are inconsistent. This meta-analysis is to evaluate CYFRA 21-1's efficacy in distinguishing OSCC.Methods: Systematic searches of Web of Science, PubMed, and CNKI (1996-2024) were conducted following the Preferred Reporting ltems for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.Results: Analysis of 693 patients and 548 controls yielded combined sensitivity (SEN) of 0.71 (95% CI: 0.68, 0.75), specificity (SPE) of 0.88 (95% CI: 0.85, 0.90), and area under the curve (AUC) of 0.927. Subgroup analysis showed higher SEN (0.88), SPE (0.93), and AUC (0.962) in saliva versus serum. Enzyme-linked immunosorbent assay (ELISA) demonstrated superior performance over electrochemiluminescent immunoassay (ECLIA) (AUC: 0.968 vs. 0.868).Conclusion: CYFRA 21-1 is effective in OSCC diagnosis, with ELISA showing better sensitivity. Saliva emerges as a promising diagnostic medium compared to serum.Registration: PROSPERO CRD42024566835.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1161-1168"},"PeriodicalIF":2.9000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2024.2405225","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/23 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Previous studies have revealed the importance of CYFRA 21-1 in the diagnosis of oral squamous cell cancer (OSCC). However, the results are inconsistent. This meta-analysis is to evaluate CYFRA 21-1's efficacy in distinguishing OSCC.

Methods: Systematic searches of Web of Science, PubMed, and CNKI (1996-2024) were conducted following the Preferred Reporting ltems for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.

Results: Analysis of 693 patients and 548 controls yielded combined sensitivity (SEN) of 0.71 (95% CI: 0.68, 0.75), specificity (SPE) of 0.88 (95% CI: 0.85, 0.90), and area under the curve (AUC) of 0.927. Subgroup analysis showed higher SEN (0.88), SPE (0.93), and AUC (0.962) in saliva versus serum. Enzyme-linked immunosorbent assay (ELISA) demonstrated superior performance over electrochemiluminescent immunoassay (ECLIA) (AUC: 0.968 vs. 0.868).

Conclusion: CYFRA 21-1 is effective in OSCC diagnosis, with ELISA showing better sensitivity. Saliva emerges as a promising diagnostic medium compared to serum.

Registration: PROSPERO CRD42024566835.

查看原文本刊更多论文

CYFRA 21-1 在口腔鳞状细胞癌中的诊断价值：一项荟萃分析。

背景：以往的研究表明，CYFRA 21-1 在诊断口腔鳞状细胞癌（OSCC）中具有重要作用。然而，研究结果并不一致。本荟萃分析旨在评估 CYFRA 21-1 在鉴别 OSCC 方面的功效：方法：按照《系统综述和荟萃分析首选报告标准》（Preferred Reporting ltems for Systematic Reviews and Meta-Analyses，PRISMA）指南对 Web of Science、PubMed 和 CNKI（1996-2024 年）进行系统检索：对 693 例患者和 548 例对照进行分析后得出的综合灵敏度 (SEN) 为 0.71（95% CI：0.68, 0.75），特异性 (SPE) 为 0.88（95% CI：0.85, 0.90），曲线下面积 (AUC) 为 0.927。亚组分析显示，唾液的 SEN（0.88）、SPE（0.93）和 AUC（0.962）均高于血清。酶联免疫吸附测定（ELISA）的性能优于电化学发光免疫测定（ECLIA）（AUC：0.968 对 0.868）：结论：CYFRA 21-1 可有效诊断 OSCC，ELISA 的灵敏度更高。结论：CYFRA 21-1 对 OSCC 诊断有效，ELISA 的灵敏度更高，与血清相比，唾液是一种很有前景的诊断介质：注册号：PREMCORD42024566835。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Anticancer Therapy 医学-肿瘤学

CiteScore

5.10

自引率

3.00%

发文量

100

审稿时长

4-8 weeks

期刊介绍： Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches. Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care. Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.